4
Changes in Ownership
Stoke Therapeutics, Inc. Filed Acc 0001415889-25-023590
Director sold 61,885 shares at an average $20.13 ($1,245,698)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kaye Edward M. MD Director | 2025-08-29 | Sale 10b5-1 | −1,029 | $20.00 | $20,580 | 152,441 | D: show line 1 in the form |
| Kaye Edward M. MD Director | 2025-09-02 | Sale 10b5-1 | −14,860 | $20.14 | $299,260 | 137,581 | D: show line 2 in the form |
| Kaye Edward M. MD Director | 2025-09-03 | Sale 10b5-1 | −45,996 | $20.13 | $925,858 | 91,585 | D: show line 3 in the form |
| Open-market sales · 61,885 sh · avg $20.13 · $1,245,698 | |||||||
Loading xslF345X05/form4-09032025_090950.xml…